Hammond M Elizabeth H, Kfoury Abdallah G
U.T.A.H. Cardiac Transplant Program, Salt Lake City, Utah, USA.
Curr Opin Cardiol. 2017 May;32(3):326-335. doi: 10.1097/HCO.0000000000000390.
This review summarizes the latest publications dealing with antibody-mediated rejection (AMR) and defines areas of controversy and future steps that may improve the outcome for patients with this virulent form of rejection.
Recent progress includes publication of standardized pathologic criteria for acute AMR by the International Society for Heart and Lung Transplantation (ISHLT) and guidelines for treatment of acute AMR by the American Heart Association, endorsed by ISHLT as well. Recently published review articles emphasize the important role of innate immune mechanisms, clarify the role of viral infection and provide insights into vascular biology and the role of innate effector populations, macrophages and dendritic cells.
Strategies for future studies are discussed in the context of these new findings and similar efforts undertaken by renal and liver allograft investigators.
本综述总结了有关抗体介导排斥反应（AMR）的最新出版物，并确定了争议领域以及未来可能改善这种恶性排斥反应患者预后的步骤。
近期进展包括国际心肺移植学会（ISHLT）发布了急性AMR的标准化病理标准，以及美国心脏协会发布的急性AMR治疗指南，该指南也得到了ISHLT的认可。最近发表的综述文章强调了固有免疫机制的重要作用，阐明了病毒感染的作用，并深入探讨了血管生物学以及固有效应细胞群体、巨噬细胞和树突状细胞的作用。
在这些新发现以及肾和肝移植研究者所做类似工作的背景下，讨论了未来研究的策略。
